Logo

Bayer Reports Results of Eliapixant in P-IIb PAGANINI Study for Patients with Refractory Chronic Cough

Share this

Bayer Reports Results of Eliapixant in P-IIb PAGANINI Study for Patients with Refractory Chronic Cough

Shots:

  • The P-IIb PAGANINI study involves assessing the efficacy- safety & tolerability of eliapixant (25- 75 or 150mg- bid) vs PBO in 310 patients with RCC for 12wks. and it lasted for 18wks. in total
  • The study met its 1EPs i.e. reduction in the 24hrs. cough count of up to 27% with 75mg dose and showed a positive benefit-risk profile with mild to moderate AEs. The results of the PAGANINI study were presented at the virtual ERS International Congress 2021
  • Eliapixant (BAY1817080- PO) is an investigational potent and selective P2X3 receptor antagonist

  | Ref: Bayer | Image: Bayer

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions